Full history for every metric is available with a Kvantra account
Abpro Corporation (ABP)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 2 | 0 | 0 | 0 |
| Operating profit | $m | -10 | -15 | |||||
| Net profit | $m | - | - | -15 | -17 | -12 | -7 | -14 |
| EPS reported | $ | -23.10 | -22.29 | |||||
| Operating cashflow per share | $ | -28.83 | -1.40 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -28.83 | -1.40 | |||||
| Free cash flow | $m | -9 | -14 | |||||
| Net debt | $m | 0 | -0 | |||||
| Book value equity | $m | -15 | -16 | |||||
| Book value per share | $ | -49.46 | -6.18 | |||||
| Number of shares | m | 0.31 | 2.61 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.09 | -0.07 | |||||
| P/S LTM | x | 91.93 | 5.78 | |||||
| P/FCF LTM | x | -1.86 | -0.08 | |||||
| EV/EBITDA LTM | x | -2.78 | -0.07 | |||||
| EV/Sales LTM | x | 94.54 | 4.71 | |||||
| Earnings Yield LTM | % | -42.99% | -340.13% | |||||
| FCF Yield | % | -53.68% | -1289.6% | |||||
| Quality | ||||||||
| ROE | % | 46.67% | 27.59% | |||||
| ROIC | % | 85.39% | 23.28% | |||||
| Operating margin | % | -5421.3% | 0.00% | |||||
| Gross margin | % | 100.00% | 0.00% | |||||
| FCF/Sales | % | -4934.4% | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +50.00% | +50.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.71 | -92.79 | |||||
| Net Debt/EBITDA | x | -0.08 | 0.05 | |||||
| EBIT/Net interest | x | -25.64 | -9.80 | |||||
| Net debt/market cap | % | 0.13% | -18.53% | |||||
| Net debt/Equity | x | -0.00 | 0.01 | |||||
| Gross debt/equity | x | -0.21 | -0.01 | |||||
Company overview
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye. The company has established strategic alliances with Abpro Bio Co. Ltd and NJCTTQ. Originally known as Abpro Corporation, the company officially changed its name to Abpro Holdings, Inc. in November 2024. Incorporated in 2004, Abpro Holdings, Inc. operates from its headquarters in Woburn, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Abpro Corporation (ABP)
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye. The company has established strategic alliances with Abpro Bio Co. Ltd and NJCTTQ. Originally known as Abpro Corporation, the company officially changed its name to Abpro Holdings, Inc. in November 2024. Incorporated in 2004, Abpro Holdings, Inc. operates from its headquarters in Woburn, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free